Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4% S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4%
Management

Quantum Biopharma appoints Napoli as trial investigator

By The Northwire Desk — AI Analysis Mar 26, 2026 · 17:17 QNTM · 5.37 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Quantum Biopharma Ltd. has appointed Dr. Salvatore Napoli, MD, as the principal investigator for its planned Phase 2 clinical trial of Lucid-21-302 (Lucid-MS), an investigational therapy targeting demyelination in multiple sclerosis.
  • The company intends to submit an Investigational New Drug (IND) application to the U.S. FDA in the coming weeks, which includes the design for the Phase 2 trial.
  • Lucid-MS is described as a first-in-class, non-immunomodulatory, neuroprotective compound that has demonstrated the ability to prevent demyelination in preclinical models.

Key Details

  • Appointment: Dr. Salvatore Napoli, MD, appointed as Principal Investigator.
  • Investigator Background: Dr. Napoli is president and medical director of the Neurology Center of New England and the MS Center of New England; holds academic appointments at Harvard Medical School; and has over 20 years of experience in MS clinical and research programs.
  • Regulatory Status: Quantum Biopharma plans to submit an IND application to the FDA in the coming weeks.
  • Trial Details: The IND includes the design for a Phase 2 trial to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, subject to regulatory clearance.
  • Drug Mechanism: Lucid-MS is a patented new chemical entity with a unique mechanism of action; it is non-immunomodulatory and neuroprotective, aimed at preventing demyelination, a hallmark of MS and other neurodegenerative diseases.
  • Corporate Structure & Assets:
    • Quantum Biopharma retains 19.86% ownership of Unbuzzd Wellness Inc. (UWI) as of Sept 30, 2025.
    • Royalty agreement with UWI: 7% of sales until $250 million is reached, then drops to 3% in perpetuity.
    • Company retains approximately $130 million in tax loss carry-forwards.
    • Quantum Biopharma retains 100% of rights to develop similar products/formulations for pharmaceutical and medical uses.
    • Maintains strategic investments through wholly owned subsidiary FSD Strategic Investments Inc. (loans secured by residential/commercial property).

Notable Quotes

  • Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs: "We are pleased to collaborate with Dr. Napoli as we advance our clinical development program... Dr. Napoli's expertise will be invaluable as we prepare for clinical evaluation of Lucid-MS."
  • Zeeshan Saeed, Chief Executive Officer: "The appointment of Dr. Napoli represents a key milestone as we advance Lucid-MS toward clinical evaluation... We believe this program underscores the potential of our approach to addressing areas of high unmet need in neurodegenerative disease."
  • Dr. Salvatore Napoli: "I look forward to working with Quantum Biopharma to evaluate this investigational approach with Lucid-MS... Continued research into therapies targeting mechanisms of MS disease progression -- including demyelination and the potential for remyelination -- is critically important for patients and remains an unmet need."
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other